Neuland Laboratories Limited — Others, 31-07-2025: Appointment

Neuland Laboratories' board has approved the financial results for the quarter ended June 30, 2025. Consolidated revenue from operations reached ₹292.75 Cr, with a net profit of ₹13.90 Cr and diluted EPS of ₹10.83. Standalone net profit was ₹13.71 Cr. The board also approved the re-appointment of Dr. Ravi Shankar Gopinath as an additional Independent Director for a five-year term, starting August 1, 2025. This decision strengthens the board with continued experienced leadership and strategic oversight.